IBM earnings up next: Can Confluent deal fuel guidance raise?

IBM reports Q1 earnings Wednesday with consensus at $1.81 EPS on $15.6 billion revenue, while investors focus on whether the earlier completion of its $11 billion Confluent acquisition will lift 2026 guidance. Analysts expect constant-currency software revenue growth above 10% and a possible increase to IBM’s full-year revenue target above 5%, aided by Red Hat strength and additional Confluent contribution. Sentiment is constructive but cautious, as the stock is down 14% year-to-date and management must address AI strategy and free cash flow guidance.

Analysis

IBM’s setup is less about a clean earnings beat and more about whether the market will re-rate the durability of its software mix after the acquisition pull-forward. The key second-order effect is that an earlier contribution from CFLT should not just lift near-term growth optics; it can also change the narrative on IBM’s ability to compound high-margin recurring revenue, which matters more than headline EPS for multiple expansion. If management raises the growth algorithm for Software, the stock can re-rate even if the quarter itself is only modestly ahead of estimates.

The market is still anchored on the old IBM problem: consulting-heavy, low multiple, slow growth. That creates asymmetry if management convinces investors that AI and hybrid cloud are becoming monetized distribution channels rather than capex themes; in that case, the selloff year-to-date becomes a positioning problem, not a fundamental one. The bigger risk is the reverse: if guidance only confirms existing expectations, the stock can lag because the easy upside from the deal pull-forward will already be in the print.

CFLT is the cleaner convexity expression here. Its economic value to IBM is higher than the standalone headline suggests because data infrastructure embedded into a larger enterprise installed base can improve retention and cross-sell, but that also means CFLT shares may be less about takeover premium and more about how much of the thesis survives post-close integration. ARM is a lower-beta beneficiary if IBM’s enterprise AI narrative gains traction, but it is more exposed to broad software multiple compression than to IBM-specific execution.

Contrarian view: the consensus may be underestimating how little the market will reward a good quarter if IBM does not explicitly frame a multi-quarter acceleration path. The stock has already absorbed skepticism around legacy modernization cannibalization; if that fear is overdone, a clean guide could trigger a sharper-than-expected squeeze. But if management leans too hard on AI rhetoric without showing tangible Software acceleration, the rally likely fades within days as investors treat it as story inflation rather than fundamental inflection.

Key Decisions for Investors

• Long IBM into the print via a tight-risk call spread or outright equity, holding 1-3 weeks post-earnings; target 8-12% upside if Software guidance is raised, stop if management only reiterates prior growth ranges.
• Pair trade: long IBM / short a basket of higher-multiple enterprise software names for 1-2 months; thesis is IBM can benefit from multiple expansion on improving quality of growth while the sector remains vulnerable to compression.
• Long CFLT on any post-close volatility if IBM signals stronger-than-expected contribution and retention; use a 1-3 month horizon with the view that strategic value increases more than near-term standalone fundamentals suggest.
• Buy IBM 1-2 month put spreads as a hedge against a guidance-only print; risk/reward is attractive if the market had already priced in a guidance raise and the stock gives back recent momentum.